Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: A review of its use in the treatment of glaucoma and ocular hypertension

Drugs and Aging

Volumn 23, Issue 12, 2006, Pages 977-995

  Frampton, James E ^a   Perry, Caroline M ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIARRHYTHMIC AGENT; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIGITALIS GLYCOSIDE; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; LATANOPROST; LATANOPROST PLUS TIMOLOL; MONOAMINE OXIDASE INHIBITOR; OPIATE; PILOCARPINE; PILOCARPINE PLUS BETAXOLOL; PILOCARPINE PLUS EPINEPHRINE; PILOCARPINE PLUS TIMOLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST; UNINDEXED DRUG;

ABDOMINAL PAIN; ABNORMAL SENSATION; BLURRED VISION; BRADYCARDIA; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG USE; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EYE BURNING; EYE DISEASE; EYE PAIN; EYE STINGING; EYE SWELLING; EYELID DISCOMFORT; EYELID DISEASE; EYELID PAIN; FLU LIKE SYNDROME; FOREIGN BODY SENSATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART BLOCK; HEART FAILURE; HUMAN; HYPOTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; LACRIMATION; LIVER METABOLISM; MONOTHERAPY; NAUSEA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SINUS BRADYCARDIA; SINUSITIS; TASTE DISORDER; THORAX PAIN; TRABECULECTOMY; TRABECULOPLASTY; UNSPECIFIED SIDE EFFECT; UROLITHIASIS; VISUAL DISORDER;

DRUG COMBINATIONS; GLAUCOMA; HUMANS; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; SULFONAMIDES; THIOPHENES; TIMOLOL; VISION;

EID: 33845604091     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200623120-00005     Document Type: Review

References (76)

1. World Health Organisation. Magnitude and causes of visual impairment [online]. Available from URL: http://www.who.int [Accessed 2005 Dec 19]
2. Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management. Drugs Aging 2005; 22 (4): 315-21
3. Lee AG, Beaver HA. Visual loss in the elderly - Part I: Chronic visual loss: what to recognize and when to refer. Clinical Geriatrics 2003; 11 (6): 46-53
4. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004 Apr; 122 (4): 532-8
5. Minassian DC, Reidy A, Coffey M, et al. Utility of predictive equations for estimating the prevalence and incidence of primary open angle glaucoma in the UK. Br J Ophthalmol 2000 Oct; 84 (10): 1159-61
6. Tuck MW, Crick RP. The age distribution of primary open angle glaucoma. Ophthalmic Epidemiol 1998 Dec; 5 (4): 173-83
7. Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997; 10: 384-403
8. American Optometric Association. Glaucoma [online]. Available from URL: http://www.aoa.org [Accessed 2005 Dec 19]
9. Bonomi L, Marchini G, Marraffa M., et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000 Jul; 107 (7): 1287-93
10. Harris A, Rechtman E, Siesky B, et al. The role of optic nerve blood flow in the pathogenesis of glaucoma. Ophthalmol Clin N Am 2005; 18: 345-53
11. Costa VP, Harris A, Stefansson E, et al. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res 2003 Nov; 22 (6): 769-805
12. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004 Apr; 15 (2): 119-26
13. The Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension [online]. Available from URL: http://www.rcophth.ac.uk [Accessed 2005 Dec 19]
14. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005; 22 (1): 1-21
15. Hoyng PFJ, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000; 59 (3): 411-34
16. Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 2000 Dec; 17: 477-96
17. Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res 2004 Mar; 78 (3): 639-51
18. Toris CB, Zhan GL, Yablonski ME, et al. Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide. J Glaucoma 2004 Jun; 13 (3): 210-5
19. Heel RC, Brogden RN, Speight TM, et al. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979; 17 (1): 38-55
20. Harris A, Jonescu-Cuypers CP, Kagemann L, et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am J Ophthalmol 2001 Oct; 132 (4): 490-5
21. Januleviciene I, Harris A, Kagemann L, et al. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand 2004 Dec; 82 (6): 730-7
22. Manni G, Centofanti M, Gregori D, et al. The pulsatile ocular blood flow behaviour in open angle glaucoma patients after replacing timolol therapy with timolol and dorzolamide fixed combination: preliminary study. Acta Ophthalmol Scand Suppl 2002; 236: 55-6
23. Martinez A, Sanchez M. A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr Med Res Opin 2006; 22 (1): 67-73
24. Arend O, Harris A, Wolter P, et al. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmol Scand 2003 Oct; 81 (5): 474-9
25. Fuchsjager-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005 Oct; 89 (10): 1293-7
26. Galassi F, Sodi A, Renieri G, et al. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica 2002 Mar-Apr; 216 (2): 123-8
27. Avunduk AM, Sari A, Akyol N, et al. The one-month effects of topical betaxolol, dorzolamide and apraclonidine on ocular blood flow velocities in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica 2001 Sep-Oct; 215 (5): 361-5
28. Martinez A, Ganzalez F, Capeans C, et al. Dorzolamide effect on ocular blood flow. Invest Ophthalmol Vis Sci 1999; 40 (6): 1270-5
29. Biollaz J, Munafo A, Buclin T, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995; 47 (5): 453-60
30. Maren TH, Conroy CW, Wynns GC, et al. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 1997; 13 (1): 23-30
31. Martens-Lobenhoffer J, Banditt P. Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet 2002; 41 (3): 197-205
32. Cosopt. (dorzolamide hydrochloride-timolol maleate ophthalmic solution) prescribing information [online]. Available from URL: http://www.cosopt.com [Accessed 2005 Dec 6]
33. Strahlman E, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996; 122: 183-94
34. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002 Jun; 240 (6): 430-5
35. Phillips CJ, Bartholemew RS, Kazl G, et al. Penetration of timolol eye drops into human aqueous humour. Br J Ophthalmol 1981; 65: 593-5
36. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998; 105: 1952-9
37. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998; 105: 1945-51
38. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004 Feb; 82 (1): 42-8
39. Susanna R Jr, Sheu WP. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther 2004 May; 26 (5): 755-68
40. Honrubia FM, Larsson LI, Spiegel D, et al. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002; 80 (6): 635-41
41. Konstas AG, Papapanos P, Tersis I, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003 Jul; 110 (7): 1357-60
42. Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 2005; 49 (3): 39-45
43. Parmaksiz S, Yuksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 2006 Jan-Feb; 16 (1): 73-80
44. Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003 Dec; 110 (12): 2362-8
45. Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol 2005 May-Jun; 15 (3): 336-42
46. Suzuki ERJ, Franklin LM, da Silva LJ, et al. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2006 Sep; 22 (9): 1799-805
47. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998; 82: 1249-53
48. Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group [see comments]. Ophthalmology 1998; 105: 1936-44
49. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003 Mar; 110 (3): 615-24
50. Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004 Apr; 13 (2): 149-57
51. Zabriskie N, Netland PA. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther 2003 Mar-Apr; 20 (2): 92-100
52. Shin DH, Feldman RM, Sheu WP. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004 Feb; 111 (2): 276-82
53. Konstas AG, Kozobolis VP, Lallos N, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/ timolol maleate 0.5%. Eye 2004 Dec; 18 (12): 1264-9
54. Nixon DR. Evaluation of the safety and efficacy of brimonidine tartrate-timolol maleate ophthalmic solution (Combigan®) and dorzolamide hydrochloride-timolol maleate ophthalmic solution (Combigan®) in patients with open-angle glaucoma or ocular hypertension [abstract no. 453-B188 plus poster]. In: the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); April 30-May 4, 2006; Ft Lauderdale (FL). Invest Ophthalmol Vis Sci 2006; 47 [online]. Available from URL: http:\www.iovs.org [Accessed 2006 Jun 6]
55. Arcieri ES, Pereira ACA, Andreo EGV, et al. Fixed combination brimonidine-timolol (Combigan®) versus fixed combination dorzolamide-timolol (Cosopt®) each given twice daily to reduce intraocular pressure in subjects with glaucoma or ocular hypertension [abstract no. E434-B169]. Invest Ophthalmol Vis Sci 2006; 47 [online]. Available from URL: http:\www.iovs.org [Accessed 2006 Jun 6]
56. Fechtner RD, McCarroll KA, Lines CR, et al. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 2005 Jun; 21 (3): 242-9
57. Lass JH, Khosrof SA, Laurence JK, et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol 1998; 116: 1003-10
58. Cosopt Ophthalmic Solution - summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2005 Dec 6]
59. American Academy of Ophthalmology Preferred Practice Patterns Committee Glaucoma Panel. Preferred practice patternTM: primary open angle glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2000
60. Goldberg I. Drugs for glaucoma. Aust Prescr 2002; 25: 142-6
61. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmology 2005 Oct; 140 (4): 598-606
62. Perry CM, McGavin JK, Culy CR, et al. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 2003; 20 (8): 597-630
63. Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 2003; 20 (12): 919-47
64. Kaluzny JJ, Szaflik J, Czechowicz-Janicka K, et al. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmol Scand 2003 Aug; 81 (4): 349-54
65. Stewart WC. Combination therapy: is the whole greater? [online]. Available from URL: http://www.revophth.com [Accessed 2006 Jan 6]
66. Fechtner R, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15: 132-5
67. Anon. Combination glaucoma medications. Clin Exp Optom 2005; 88 (2): 119-20
68. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independant risk factor in patients with glaucoma. J Glaucoma 2000 Apr; 9 (2): 134-42
69. Pajic B. Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices. Curr Med Res Opin 2003; 19 (2): 95-101
70. Henderer JD, Wilson RP, Moster MR, et al. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg. J Glaucoma 2005 Aug; 14 (4): 267-70
71. Akman A, Cetinkaya A, Akova YA, et al. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye 2005 Feb; 19 (2): 145-51
72. Gugleta K, Orgul S, Flammer J. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices. Curr Med Res Opin 2003; 19 (4): 330-5
73. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000 Dec; 130 (6): 832-3
74. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006; 24 (3): 251-64
75. Doyle JJ, Casciano JC, Walt JG. Cost-effectiveness of bimatoprost 0.03% versus a combination product of timolol 0.5% and dorzolamide 2.0% for glaucoma [abstract no. PES4 plus poster]. Value Health 2003 May-Jun; 6: 238
76. Soto J, De Miguel V. A pharmacoeconomic analysis of the fixed combination latanoprost/timolol versus dorzolamide/timolol in the treatment of patients with glaucoma in Spain [abstract no. PES7 plus poster]. Value Health 2004 Nov-2004; 7: 747